HCVcc-IN-2 

HCVcc-IN-2 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. HCVcc-IN-2 has high inhibition against the three cell line from CNS cancer (SF-539 and SNB-75), colon cancer (HCT-116), and renal cancer (A498)^[1].

HCVcc-IN-2 (compound 6c) (0.1, 1, 10, and 100 μg/mL; 1 h) shows antiviral activities against a variety of viruses such as coxsackievirus B4 (CBV4), hepatitis A virus HM 175 (HAV), hepatitis C genotype 4 (HCVcc), adenovirus type 7 (HAdV7), and herpes simplex virus 1 (HSV-1) with viral reduction rates of 83.3%, 63.3%, 40%, 63.3%, and 30%, respectively^[1].
HCVcc-IN-2 (0.55-1.9 μg/mL; 1 h) inhibits various virus with IC₅₀ of 0.55 μg/mL (herpes simplex virus), 0.76 μg/mL (HCVcc genotype virus), and 0.76 μg/mL (coxsackievirus B4), respectively; or with CC₅₀ of 1.8 μg/mL (herpes simplex virus), 1.9 μg/mL (HCVcc genotype virus), and 1.9 μg/mL (coxsackievirus B4), respectively^[1].
HCVcc-IN-2 (7.68-16.01 μg/mL; ) inhibits hepatitis C virus NS3/4A and HSV- USP7 protease enzyme with IC₅₀s of 16.01 μg/mL and 7.68 μg/mL^[1].
HCVcc-IN-2 (0.01 mM; 24 h) has low cytotoxicity, shows high inhibition against two cell lines, SK-MEL-5, OVCAR-4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

777.68

C₃₂H₂₉BrN₂O₁₀S₃

2977251-02-6

O=C(C1=C(N)C(C2=NC3=CC=CC=C3S2)=C(S[C@H]4[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@](OC(C)=O)([H])[C@@H](COC(C)=O)O4)S1)C5=CC=C(Br)C=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Azzam et al. Novel Thiophene Thioglycosides Substituted with the Benzothiazole Moiety: Synthesis, Characterization, Antiviral and Anticancer Evaluations, and NS3/4A and USP7 Enzyme Inhibitions. ACS Omega. 2022 Sep 29;7(40):35656-35667.  [Content Brief]